Conclusion. In this trial, treatment with baminercept failed to significantly improve glandular and extraglandular disease in patients with primary SS, despite evidence from mechanistic studies showing that it blocks LTbR signaling.
Primary Sj€ ogren's syndrome (SS) is characterized by lacrimal and salivary gland dysfunction, systemic manifestations affecting various organ systems, serum production of Ro/SSA autoantibodies, and an increased risk of B cell lymphoma (1, 2) . Treatment of primary SS has been hampered by the lack of approved disease-modifying therapy. Ideally, therapies for primary SS would target pathways involved in driving disease pathogenesis. In the target tissue, Th1, Th17, and follicular T helper (Tfh) cells, B cells, and dendritic cells, as well as increased expression of type 1 and type 2 interferons (IFNs) and BAFF, appear to be major contributing factors in these mechanisms (3) . Despite evidence implicating B cells in this disease process (4) (5) (6) (7) , treatment of patients with primary SS with rituximab, a CD20 B cell-depleting antibody, has failed to show significant clinical benefit in 2 randomized, controlled trials (8, 9) .
In primary SS, lymphoid infiltrates in the salivary glands often form ectopic lymphoid organ structures, comprising distinct B and T cell compartments, high endothelial venules (HEV), and follicular dendritic cell networks that depend on lymphotoxin b receptor (LTbR) signaling for their development and maintenance (10, 11) . LTbR binds to LTa/b heterotrimers and LIGHT (also known as tumor necrosis factor superfamily member 14 [TNFSF14] ). LTa/b heterotrimers are expressed on the surface of hematopoietic cells, including mature B, T, and natural killer cells (12) .
In mice, blockade of the LTbR system reduces expression of HEV addressin and inhibits entry of lymphocytes into lymph nodes and mucosal environments, resulting in blood lymphocytosis (13) . LTbR-Ig treatment in male NOD mice, an experimental model of SS, inhibits glandular inflammation, blocks HEV formation, and partially restores salivary flow (14) . Baminercept, an LTbR-Ig fusion protein, and pacteclizumab, an anti-LTa antibody, have been investigated as treatments for rheumatoid arthritis (RA), but they failed, in both instances, to produce significant clinical efficacy (15, 16) . Nevertheless, treatment of RA patients with baminercept altered lymphocyte trafficking and inhibited the whole blood IFN signature, in accordance with its predicted mechanisms of action (15) . Based on a strong scientific rationale, we evaluated baminercept therapy in a randomized, placebo-controlled trial in patients with primary SS, and explored its impact on LT/LIGHTdependent pathways.
PATIENTS AND METHODS
Study population. Eligible subjects were ages 18-75 years, met the American-European Consensus Group classification criteria for SS (17) , had a stimulated whole salivary flow (SWSF) rate ≥0.1 ml/minute, and had either severe parotid gland swelling or 1 or more of the following systemic disease manifestations: fatigue (>50 mm on a 100-mm visual analog scale [VAS] ), joint pain (>50 mm on a 100-mm VAS), peripheral neuropathy (documented by nerve conduction velocity study), interstitial lung disease (documented by radiography and/or evidence of lung abnormalities on pulmonary function tests), leukocytoclastic vasculitis, renal tubular acidosis, interstitial nephritis, or other extraglandular manifestations causing organ system dysfunction. Participants were allowed to take prednisone if the dosage was ≤10 mg/day and if it remained stable at the same dose during the treatment period. If patients were taking hydroxychloroquine, it was maintained during the treatment period at that same dose as at the time of study entry. Subjects taking a cholinergic stimulant (e.g., pilocarpine, cevimeline) were allowed to continue these medications. To be included in the study, women of childbearing age agreed to use acceptable means of birth control.
Key exclusion criteria included a diagnosis of another connective tissue disease, severe pulmonary disease (resting oxygen saturation <92%, forced vital capacity <50% of predicted, or lung diffusing capacity for carbon monoxide <50%), active or recurrent infection, a history of malignancy within the last 5 years (except for a resected basal or squamous cell skin carcinoma, cervical dysplasia, or in situ cervical cancer grade I), a positive pregnancy test result, or an abnormal laboratory test result (hemoglobin <9.0 gm/dl, neutrophil count <1,500/ mm 3 , platelet count <100,000/mm 3 , serum creatinine ≥2.0 mg/ dl, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >1.5 times the upper limit of normal). Subjects were also excluded if they were taking medications with potent anticholinergic side effects (see Supplementary Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40513/abstract) or had received treatment with biologic agents or an immunosuppressive drug within a prespecified washout period.
Study oversight and design. The study was designed in collaboration with investigators at each site and was approved by the Institutional Review Board at each site. All clinical data were collected in accordance with the Guidelines for Good Clinical Practice. Statistical analyses were performed by statisticians at the Statistical and Clinical Coordinating Center (SACCC).
The study was designed as a phase II multicenter, randomized, double-blind, placebo-controlled trial of baminercept in patients with primary SS. Eligible subjects were randomly allocated in a 2:1 ratio to receive 24 weekly subcutaneous injections of 100 mg of study drug (baminercept or matching placebo; supplied by Biogen) starting at the baseline visit and ending at week 23. Randomization was stratified by site. The dose was chosen based on pharmacokinetic, pharmacodynamic, and safety data from healthy volunteers and patients with RA enrolled in previous trials of baminercept. Since identification of elevated lymphocyte counts could unmask a patient's treatment assignment, these results were only available to personnel at the SACCC, the National Institutes of Allergy and Infectious Diseases safety officer, and a physician subinvestigator at each site who was not involved in the subject assessments.
Injections were self-administered on the same day (AE1 day) each week. The first 3 injections were self-administered in the clinic under direct observation, at baseline, week 1, and week 2, while subsequent injections were given at home. Subjects returned at weeks 4, 8, 12, 18, 24, 30, 36 , and 48 for safety and efficacy assessments and blood sampling for mechanistic studies.
Clinical assessments. Salivary flow was measured using a previously described whole saliva technique (18) . Participants were instructed to withhold their dose of any secretagogue (pilocarpine or cevimeline) for 48 hours before the visit and to take nothing by mouth for at least 60 minutes before saliva collection. First, the unstimulated whole salivary flow (UWSF) rate was measured for 15 minutes, and then the SWSF rate was measured in a 15-minute collection, at 60 minutes following a single 5-mg dose of pilocarpine.
Ophthalmologists measured tear flow in unanesthetized patients using the Schirmer I test (19) , and assessed ocular dryness by lissamine green staining of the temporal and nasal conjunctiva of each eye, with results scored according to a scoring system in which the conjunctival surface of each eye was divided into 6 areas and a quantitative scale (scores of 0-3, ranging from 0 = no staining to 3 = maximum staining) was used to grade each of the areas (total score 0-18) (19) . VAS scores (scale 0-100 mm) were used for self-assessment of symptoms, including fatigue, overall dryness, and joint pain, as well as patient's and physician's global assessments of disease severity. For evaluation of systemic disease activity, the European League Against Rheumatism Sj€ ogren's Syndrome Disease Activity Index (ESSDAI) was determined at baseline and week 24 (20) . Quality of life was evaluated using the 36-item Short Form (SF-36) Health Survey. We also included in the design an optional labial salivary gland biopsy at weeks 0 and 24; however, only 9 paired samples were available for this substudy and were not further analyzed.
Immunizations with vaccines. To assess immunocompetency, keyhole limpet hemocyanin (KLH) (Immunothel; Biosyn) and a pneumococcal polysaccharide vaccine (Pneumovax 23; Merck and Co.) were administered to patients at week 8. KLH was given as a single 1-mg subcutaneous injection reconstituted in 0.5 ml of excipient and then emulsified with Montanide ISA-51 VG (Seppic), in accordance with the manufacturer's instructions. Pneumovax 23 is a US Food and Drug Administration-approved polyvalent vaccine containing highly purified capsular polysaccharides from Streptococcus pneumoniae.
Antibody responses to KLH were assessed using commercial assays from Alpha Diagnostics International. IgG and IgM anti-KLH levels were calculated (in units/ml) based on the assay's standard curve, using dilutions of 1:10 or 1:100. Values >160,000 units/ml were not further titrated and were reported as the maximum measured value. Antibodies to the 23 serotypes in Pneumovax (Quest Diagnostics) were also measured.
Flow cytometry. Patients' blood samples were collected into CPT tubes (BD Biosciences) at baseline and at weeks 4, 12, 24, and 48, and samples were shipped overnight from participating sites to a centralized location (Oklahoma Medical Research Foundation) for processing, where they were banked in liquid nitrogen until used. For analysis of the B and T cell subsets, peripheral blood mononuclear cells were stained at 4°C for 30 minutes in fluorescence-activated cell sorting buffer (phosphate buffered saline with 0.5% bovine serum albumin) with a cocktail of fluorochrome-conjugated antibodies (see Supplementary Methods for further details, http://onlinelibrary.wiley.com/doi/ 10.1002/art.40513/abstract).
Measurement of serum levels of autoantibodies, chemokines, and cytokines. Serum autoantibodies to Ro/SSA composite (Ro 52 and Ro 60) and to La/SSB were assayed using a bead-based multiplex assay on a BioPlex 2200 platform (Bio-Rad Technologies), as described previously (21) .
Levels of interferon-c-inducible protein 10 (IP-10) were assessed using an xMAP Bioplex 200 array system (Bio-Rad Technologies), as described previously (22) . Results were quantified as the median fluorescence intensity (MFI), with values normalized to those of a known control serum. Levels of BAFF were measured using a specific enzyme-linked immunosorbent assay (ELISA) (R&D Systems and Affymetrix/eBioscience) in accordance with the manufacturers' protocol. CXCL13 and LIGHTwere also measured using an ELISA (Human CD258/LIGHT Ready-Set-Go and ProcartaPlex Human BLC/CXCL13 Simplex; Affymetrix/eBioscience).
End points. The primary efficacy end point was the change in the SWSF rate between screening and week 24. Key secondary efficacy end points included the change in the UWSF rate, ESSDAI, VAS scores for patient's self-assessments of fatigue, overall dryness, and joint pain, VAS scores for patient's and physician's global assessments of disease activity, results of the Schirmer's I test for tear flow, ocular staining for eye dryness, and SF-36 scores of general health status. Salivary flow was calculated as the amount of saliva divided by the duration, in minutes, of collection. The proportion of subjects experiencing any adverse event (AE) of grade 3 or above was a safety end point of particular interest.
Statistical analysis. Subjects who had received at least 1 dose of study treatment and had undergone a SWSF assessment at screening were included in the modified intent-to-treat (mITT) population. For the primary mITT analysis, missing data for the SWSF rate at week 24 were imputed by carrying forward the last observed postbaseline value. However, as prespecified in the analysis plan, 1 subject without a postbaseline SWSF value was excluded from the primary analysis. An analysis of covariance (ANCOVA) model was used for the primary analysis comparing the change in the SWSF rate between treatment groups from screening to week 24, adjusted for the screening value.
ANCOVA models were also used to test secondary end points for changes from baseline in continuous outcomes (except in the analyses of B cell and Tcell percentages, and anti-KLH and antipneumococcal antibody responses); baseline/screening values were considered covariates. Wilcoxon's rank sum test was used to compare the change from baseline in the frequency of B cell and T cell percentages across treatment groups and the change from baseline in the anti-KLH and antipneumococcal antibody responses. Fisher's exact test was used for categorical outcomes. Subjects with available data in the mITT population were used for secondary efficacy and mechanistic analyses. The safety population consisted of all subjects who had received at least 1 dose of study drug. Secondary analyses to support the primary and secondary objectives were considered exploratory; P values are presented without adjustment for multiple comparisons.
For the primary analysis, the study was powered to detect a significant treatment group difference in the change in SWSF rate from screening to week 24. Assumptions were informed using data from prior studies (18, 23) . A change in the SWSF rate of 0.02 ml/minute was assumed to be the maximum in the placebo arm. In the baminercept group, a change of 0.33 1472 ST.CLAIR ET AL ml/minute was considered to represent clinically meaningful improvement. The standard deviation was assumed to be 0.4 in both arms. Based on a 2-sided t-test with an alpha level of 0.05, and allowing for a 10% dropout rate, we estimated that the study would need 72 subjects, randomized to a treatment group at a ratio of 2:1, to achieve 80% power to detect a significant between-group difference.
RESULTS
Characteristics of the study subjects. Study enrollment was terminated early because of expiration of the study drug. Of the 104 subjects screened, 52 subjects were eligible and randomized into the trial (details on the distribution of patients are shown in Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40513/abstract). All 33 subjects in the baminercept group and 19 subjects in the placebo group were included in the mITT and safety samples. However, 1 baminercept-treated patient was excluded from the primary end point analysis because this individual had no posttreatment measurements of salivary flow. Demographic and baseline clinical characteristics were similar between the treatment groups, except that the tear flow in the right eye was slightly higher among subjects in the placebo group (Table 1 ). All subjects had low levels of systemic disease activity, as indicated by the low mean ESSDAI score at entry.
Clinical efficacy. The primary outcome, the change in the SWSF rate between screening and week 24, was not significantly different between the treatment groups (P = 0.33) ( Table 2 ). The adjusted mean reduction in the ESS-DAI score in the baminercept group was numerically small, and was not statistically significantly different from that in the placebo group (À1.23 versus À0.15; P = 0.104) ( Table 2  and Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40513/abstract). Treatment groups also did not significantly differ in the change from baseline to week 24 in the UWSF rate, physician's global assessment of disease severity, patient's assessment of symptoms, ocular staining score for eye dryness, and SF-36 score ( Table 2) . The adjusted mean change from baseline to week 24 in the Schirmer I test results for tear flow in the right eye was statistically significantly different between the treatment groups (P = 0.036), but this difference could be attributed to a decline in tear flow in the placebo group. Adverse events. The incidence of AEs was similar between the 2 treatment groups. However, AEs of grade 3 or higher were more frequent in the baminercept treatment group than in the placebo group (P = 0.50) ( Table 3) . Treatment-emergent AEs are summarized in Supplementary Table 2 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40513/ abstract). Notable AEs occurring in more than 5% of patients and being more common in the baminercept group than in the placebo group included, but were not limited to, injection site reactions, weight decrease, vomiting, upper abdominal pain, headache, paresthesia, cough, hepatobiliary disease, lymphopenia, anemia, and hypercholesterolemia. Upper respiratory infection was documented in 8 patients (24.2%) in the baminercept group and 3 patients (15.8%) in the placebo group.
There were 5 serious AEs (SAEs) in the baminercept group and 1 SAE in the placebo group during the treatment phase. Two of the SAEs in the baminercept group were categorized as hepatobiliary injury, and characterized by reversible grade 3 elevations in liver enzyme values; 1 of these patients had a reversible elevation in bilirubin levels (see Supplementary Results, available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40513/abstract). Other SAEs observed in patients in the baminercept treatment group were breast cancer, pleurisy, and hospitalization for vasovagal syncope that were determined by the investigator to be either unlikely related, possibly related, or unrelated to the study drug, respectively. The SAE in the placebo group † Primary end point statistics included all subjects in the modified intent-to-treat (mITT) population who had a postbaseline value for the stimulated whole salivary flow (SWSF) rate. Results were consistent in the analysis when we assumed that there was no change from baseline in the baminercept-treated patient who did not have a postbaseline SWSF assessment (last observation carried forward). ‡ A total of 27 patients and 16 patients in the baminercept and placebo arms, respectively, were available for the UWSF rate, Schirmer I test for tear flow, and total ocular staining score. Only the Schirmer I test results from the right eye were significantly different between the treatment groups (P = 0.036). § A total of 29 patients and 17 patients in the baminercept and placebo arms, respectively, were available for this analysis. involved a patient who was hospitalized because of shortness of breath. Elevated liver enzyme levels occurred with greater frequency in the baminercept group than in the placebo group, including in the 2 previously mentioned patients who experienced grade 3 elevations in transaminase levels (see Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40513/abstract). There were no other significant changes in serum chemistry values, hemoglobin concentrations, total leukocyte counts, or platelet counts. However, a grade 4 neutropenia was observed in 1 patient in the baminercept group, which was judged by the investigator to be unlikely to be related to the study drug.
Response to KLH and Pneumovax 23 immunizations. To determine whether baminercept therapy could inhibit an antigen-specific response, patients were immunized at week 8 with KLH/Montanide and Pneumovax 23, and measurements of antibody responses were subsequently conducted at week 12. In this study, baminercept therapy did not suppress the antibody response to KLH, which is a T cell-dependent response, or the antibody response to the different serotypes in the pneumococcal polysaccharide vaccine, which is a T cell-independent response (see Supplementary Figures 2 and 3 Serum levels of select autoantibodies, complement, cytokines, and chemokines. Serum levels of Ro/SSA and La/SSB autoantibodies, as well as serum IgG levels, did not change during treatment (see Supplementary Table 4 on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40513/abstract). Serum C3 complement levels trended higher during treatment in the baminercept group, although the changes were not significantly different between the 2 groups (adjusted mean change 7.02 versus À0.15 mg/dl; P = 0.168). In parallel, serum levels of C4 complement also increased in the baminercept group relative to the placebo group (adjusted mean change 4.96 versus À0.31 mg/dl; P = 0.003) (see results in Supplementary Table 4) .
Baminercept and pateclizumab treatment have been shown to lower serum CXCL13 levels in patients with RA (see ref. 16 and Browning JT: unpublished observations) and to reduce CXCL13 expression in isolated lacrimal gland homogenates from mice in a model of SS (14) . In our study, we found that baminercept therapy Between-group differences were significant only for levels of CXCL13 (P = 0.038). IP-10 = interferon-c-inducible protein 10 (CXCL10).
lead to a greater reduction in serum CXCL13 levels than that in the placebo group (adjusted mean change À104.7 versus À12.7 pg/ml; P = 0.038) ( Table 4 ). In contrast, baminercept treatment failed to significantly diminish the serum levels of BAFF, LIGHT, or IP-10 as compared to the placebo group (Table 4 ). The elevations in serum levels of LIGHT detected in a previous baminercept study (15) were not observed herein, possibly due to interference from baminercept in our assay, which had been taken into account in the previous work.
Changes in circulating B and T cell subsets. Baminercept therapy was associated with an increase in blood lymphocyte counts from baseline to week 24 relative to placebo (adjusted mean change 0.75 9 10 9 cells/liter versus 0.05 9 10 9 cells/liter; P ≤ 0.001), with a recovery toward baseline values through week 48 (see Supplementary Figure 4 on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40513/abstract). Likewise, the frequency of circulating CD19+ B cells trended higher during baminercept therapy; the adjusted mean change was significantly greater in the baminercept group than in the placebo group at week 4 (P = 0.006) and at week 12 (P = 0.005) ( Figure 1A ). In contrast, no significant changes were observed in the percentage of circulating CD3+, CD4+, and CD8+ T cells (see Supplementary Figure 5 on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40513/abstract).
To investigate the effects of baminercept therapy on circulating B cell subsets, we analyzed available samples from 27 patients in the baminercept group and 13 Results are presented as box plots, where each box represents the 25th to 75th percentiles, lines inside the boxes represent the median, whiskers outside the boxes represent the 10th and 90th percentiles (calculated as Q1 -1.5 9 IQR and Q3 + 1.5 9 IQR, respectively, where Q represents quartile and IQR represents interquartile range), and triangles indicate the mean. Differences in the change from baseline between the baminercept and placebo treatment groups were as follows: A, P = 0.006 at week 4, P = 0.005 at week 12, and P = 0.320 at week 24; B, P = 0.244 at week 4, P = 0.122 at week 12, and P = 0.033 at week 24; C, P = 0.357 at week 4, P = 0.820 at week 12, and P = 0.162 at week 24; D, P = 0.159 at week 4, P = 0.066 at week 4, and P = 0.027 at week 24. * = P < 0.05; ** = P < 0.01 versus placebo, by Wilcoxon's rank sum test. patients in the placebo group using the Bm1-Bm5 classification (4) . Baseline values are shown in Supplementary  Figure 6 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 40513/abstract). Most of the blood Bm2 cells were CD21+ resting naive B cells (>99%), whereas the Bm5 cell compartment comprised CD21+ resting memory cells (~60%) and CD21À activated memory cells (~40%) (data not shown). CD21 is expressed on resting memory B cells and is down-regulated upon activation (24) . The median numbers of circulating CD21 À/low B cells have been reported to be higher in patients with primary SS than in controls (25) . In one study, CD21 expression was lower on both CD27+IgD+ unswitched and CD27+IgDÀ switched memory B cells (26) . For this post hoc analysis, changes in the percentage of a given B cell subset were considered to be significant if the 2 groups differed significantly (P < 0.05) at week 24 of treatment.
We hypothesized that the reductions in CXCL13 levels observed with baminercept therapy would result in fewer CXCR5-expressing B cells migrating from the circulation into inflamed salivary glands and reactive lymphoid tissue. Consistent with this hypothesis, the changes in the frequencies of resting naive (Bm2 CD21+) and memory (Bm5 CD21+) cells expressing CXCR5 were significantly greater at week 24 in the baminercept group compared to the placebo group (Figures 1B and D) . Alternatively, the loss of HEV portals could account for the observed changes in B cell frequencies. In contrast, the percentages of (Bm5 CD21À) CXCR5+ memory B Results are presented as box plots, where each box represents the 25th to 75th percentiles, lines inside the boxes represent the median, whiskers outside the boxes represent the 10th and 90th percentiles (calculated as Q1 -1.5 9 IQR and Q3 + 1.5 9 IQR, respectively, where Q represents quartile and IQR represents interquartile range), and triangles indicate the mean. Differences in the change from baseline between the baminercept and placebo treatment groups were as follows: A, P = 0.005 at week 4, P = 0.121 at week 12, and P = 0.043 at week 24; B, P = 0.010 at week 4, P = 0.020 at week 12, and P = 0.096 at week 24; C, P = 0.138 at week 4, P = 0.180 at week 12, and P = 0.832 at week 24; D, P = 0.020 at week 4, P = 0.067 at week 12, and P = 0.785 at week 24. * = P < 0.05; ** = P < 0.01 versus placebo, by Wilcoxon's rank sum test. cells were not significantly altered by baminercept treatment ( Figure 1C) . No significant changes were observed in the other blood CD19+ B cell compartments, including the CXCR4+ and CXCR4À B cell subsets analyzed in this study (data not shown).
We also analyzed 144 samples from 34 patients (baminercept n = 23, placebo n = 11) for treatmentrelated changes in blood T cell subsets. Baseline values are shown in Supplementary Figure 7 (available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40513/abstract). Blood T central memory (T CM ) cells express CD62L (L-selectin) and CCR7, while T effector memory (T EM ) cells are CD62LÀ and CCR7À (27) . Both CCL19 and CCL21, the ligands for CCR7, are regulated by the LT/LIGHT pathway; they promote homing of T cells to lymphoid tissue (28) and are up-regulated in salivary gland tissue from patients with primary SS (29, 30) . In the previous study of RA patients, baminercept therapy produced a decrease in serum levels of CCL19 and CCL21 (Browning JT: personal communication). At week 24, the baminercept-treated patients showed a significant increase in the percentage of circulating CCR7+CD45RAÀ CD4+ T CM cells (Figure 2A ), but there was no significant change in the percentage of CCR7+CD45RAÀCD8+ T CM cells ( Figure 2B ). However, the percentage of CCR7+CD45RAÀ CD8+ T CM cells was numerically higher at week 24 in the baminercept group and, by week 48, had trended toward baseline values. These results suggest that baminercept therapy inhibits the migration of T CM cells through HEV into lymphoid and nonlymphoid tissue.
No significant differences between treatment groups were noted with regard to changes in the frequencies of CCR7+CD45RA+ naive CD4+ and CD8+ T cells ( Figures 2C and D) , which also express CD62L and recirculate through secondary lymphoid tissue via HEV. No significant differences between treatment groups were found at week 24 in the frequencies of CCR7ÀCD45RAÀ CD4+ and CD8+ effector memory T EM cells and CCR7ÀCD45RA+ CD4+ and CD8+ effector memory T EMRA cells (see Supplementary Figures 8 and 9 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40513/abstract).
Blood memory Tfh cells are a heterogeneous population that can be grouped into 3 major subsets, Tfh1, Tfh2, and Tfh3 cell subsets, and then further subdivided into quiescent and activated subsets based on their differential expression of programmed cell death 1 (PD-1), CCR7, and inducible T cell costimulator (ICOS) (31). We did not detect a change in circulating memory Tfh cells, which also express CXCR5 (31) . Baminercept therapy did not appear to change the frequency of blood Th1, Th17, or regulatory T cells (see Supplementary Figure 10 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40513/abstract).
DISCUSSION
In this study, treatment with baminercept, an LTbR-Ig fusion protein, was not effective in improving the glandular signs and symptoms of primary SS. The study had several strengths, including its randomized, doubleblind, placebo-controlled design and the breadth of the clinical assessments. The low ESSDAI scores at entry hampered our ability to determine whether baminercept could reduce systemic disease activity. Physicians' estimates of low, moderate, and high disease activity have been correlated with ESSDAI scores of <5, 5-13, and ≥14, respectively, and a decrease in these estimates of ≥3 points has been defined as minimal clinically important improvement (32) . Our study population had low disease activity by these criteria, and the adjusted mean change in the ESSDAI score of À1.23 (95% CI À2.03, À0.43) during baminercept treatment fell below the 3-point threshold. Although the small sample size was a limitation of this study, achieving our target sample size of 72 subjects would not have likely changed these outcomes.
Two cases of reversible hepatic injury were reported in the baminercept group. In nonclinical toxicology studies, maternal liver toxicity was observed at the highest dose tested (100 mg/kg) in some pregnant rats, but not in other species (cynomolgous monkeys) or nonpregnant rats (unpublished results from Biogen). Three SAEs involving changes in liver function test results have been reported in baminercept-treated patients with RA (unpublished results from Biogen). In two phase II clinical trials involving patients with RA, elevations in the levels of ASTand ALT were noted in 2% of baminercept-treated patients compared to fewer than 1% of placebo-treated patients (15) . No liver-related SAEs or elevated liver enzyme levels were reported in patients with RA receiving pateclizumab, a monoclonal antibody against LTa (16) .
Membrane LT is critical for regulating the expression of chemokines and homing of immune cells to lymphoid and nonlymphoid tissues (11, 33) . Our finding that baminercept therapy reduced the plasma levels of CXCL13 is consistent with the results of animal studies and previous clinical investigations (14, 34, 35) and may account for the corresponding increase in the frequency of circulating Bm2 CD21+ naive and memory Bm5 CD21+ B cells expressing CXCR5, which is the receptor for CXCL13. On the other hand, baminercept therapy did not alter the percentage of CXCR5-expressing Bm5 CD21À activated memory B cells. The effects of LTbR 1478 ST.CLAIR ET AL signaling on the dynamics of recirculating B cell subsets are likely complex and incompletely understood. Circulating memory T cells have been separated into distinct subsets based on their proliferative capacity, effector function, and migration properties. T CM cells are CD62L+CCR7+, produce interleukin-2, show substantial proliferative capacity, and are prominent in secondary lymphoid organs, while T EM cells are CD62LÀCCR7À, produce IFNc, show less proliferative potential, and localize mostly in peripheral tissue (27, 36, 37) . CCR7, which functions to coordinate trafficking of various Tcell subsets through secondary lymphoid and nonlymphoid tissue, is highly expressed within immune cell aggregates and HEV-like structures of inflamed salivary gland tissue from patients with primary SS (29, 30) . The finding that baminercept therapy increased the frequency of circulating T CM cells, and not the frequency of blood T EM cells, in our study supports the hypothesis that the HEV network was disrupted by inhibition of LTbR signaling. However, we interpret these results cautiously, because of the limited number of samples available for this analysis and the lack of labial salivary gland biopsy samples to corroborate this interpretation.
We did not observe a treatment-related change in circulating Tfh cells, which also express CXCR5. The heterogeneity of the blood Tfh compartment may have obscured our ability to detect changes in this subset. In an NOD mouse model of SS, LTbR-Ig treatment differentially impacted infiltrating CD4+ T cell subsets, markedly diminishing the PD1ÀICOSÀ naive cell subset while only slightly affecting the putatively pathogenic PD-1 high ICOS high and PD-1 low ICOS low cell subsets (35) , possibly explaining the lack of efficacy of baminercept in our current study.
In summary, 24 weeks of baminercept therapy was ineffective for improving the glandular dysfunction in patients with primary SS. Despite this lack of treatment efficacy, our mechanistic analysis showed significant effects of baminercept therapy on LT/LIGHT-dependent pathways. These strong biologic effects on pathways of known pathogenic significance raise the possibility that blocking LTbR signaling might be of therapeutic benefit at earlier stages of the disease.
